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Background and Purpose This article describes several ethical, legal, and social
issues typical of international genetics biobanking, as encountered in the Type 1
Diabetes Genetics Consortium (T1DGC).
Methods By studying the examples set and lessons learned from other interna-
tional biobanking studies and by devoting considerable time and resources to
identifying, addressing, and continually monitoring ethical and regulatory con-
cerns, T1DGC was able to minimize the problems reported by some earlier studies.
Conclusions Several important conclusions can be drawn based on the experience
in this study: (1) Basic international standards for research ethics review and
informed consent are broadly consistent across developed countries. (2) When
consent forms are adapted locally and translated into different languages,
discrepancies are inevitable and therefore require prompt central review and
resolution before research is initiated. (3) Providing separate ‘check-box’ consent for
different elements of a study creates confusion and may not be essential.
(4) Creating immortalized cell lines to aid future research is broadly acceptable,
both in the US and internationally. (5) Imposing some limits on the use of stored
samples aids in obtaining ethics approvals worldwide. (6) Allowing potential
commercial uses of donated samples is controversial in some Asian countries.
(7) Obtaining government approvals can be labor-intensive and time-consuming,
and can require legal and diplomatic skills. Clinical Trials 2010; 7: S33–S45. http://
ctj.sagepub.com
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The Type 1 Diabetes Genetics Consortium (T1DGC)
is an international collaborative project where
34 countries organized into four networks worked
toward the common goal of collecting and charac-
terizing individuals with type 1 diabetes in order to
develop resources for the purpose of identifying
genes that increase (or decrease) an individual’s risk
for type 1 diabetes. The basic mechanisms that
trigger type 1 diabetes are poorly understood, and
T1DGC has also facilitated the study of autoimmu-
nity as a general phenomenon that may be impli-
cated causally in type 1 diabetes. A complete list of
the countries that participated in each of the four
T1DGC networks can be found on the study
website (www.t1dgc.org).
The T1DGC has fostered international collabo-
rative gene identification in type 1 diabetes by
(1) conducting research worldwide to ascertain,
study, and establish a renewable source of DNA
from thousands of families with at least two type 1
diabetic children and two parents (if available);
families with one type 1 diabetic child and two
parents; and matched pairs of diabetic cases and
controls; (2) creating a database for the scientific
community with standardized clinical, genetic, and
medical history information that would facilitate
the search for type 1 diabetes susceptibility genes,
and a centralized DNA repository to allow targeted
studies of genetic structure and function for type 1
diabetes and other autoimmune diseases; and
(3) providing opportunities to extend the results
of research to develop methods of risk prediction,
prevention, and therapy in the area of type 1
diabetes.
The scale and complexity of this international
project, along with its targeted focus on type 1
diabetes and other autoimmune diseases, highlight
certain ethical and policy issues that are confronted
with increasing frequency both in the field and in
scholarship, as large sample repository research
becomes more widespread. National biobanks have
been established in many countries, and reposito-
ries to facilitate research investigating gene–envi-
ronment interactions, pharmacogenetics, and a
wide range of disorders and conditions have been
established by the pharmaceutical industry, disease
constituency groups, cooperative research groups,
the National Institutes of Health (NIH), and even
hospital consortia [1]. Numerous attempts to
develop consistent and workable policies for bio-
repositories on a range of important ethical and
policy questions, including scope of consent,
oversight of future uses, recontact of participants,
privacy and confidentiality, and intellectual
property considerations are ongoing [2–8].
Our experiences with the Consortium in addressing
many of these issues over time and all over the
world provide practical examples to help inform
biobanking policy and scholarship.
Methods, results, and discussion
Given the international nature of the Consortium,
the T1DGC was constructed around four interna-
tional networks: Asia-Pacific, Europe, North
America, and United Kingdom. At the outset of
the study, a 10-person Ethical, Legal, and Social
Implications (ELSI) Committee was created with
one or two representatives from each network, the
Coordinating Center (Wake Forest University
Health Sciences), and the two funding agencies
(National Institute of Diabetes and Digestive and
Kidney Disease (NIDDK) and Juvenile Diabetes
Research Foundation). It proved to be essential to
have a committee with broad interdisciplinary and
international composition. At various times in the
study, ELSI issues required not only ethical exper-
tise but also legal and diplomatic skills to resolve.
The chair of the ELSI Committee devoted 10% of
his time to this function over the course of the
study. In part, this intensive engagement was
needed to meet in person with researchers in each
network to explain the nature and source of U.S.-
imposed regulatory requirements dealing with the
ethics of research. It was necessary both to reassure
researchers in some countries that ethical and
privacy safeguards were adequate in the United
States and to explain the need for requirements
that some international researchers viewed as
excessive or arbitrary.
Basic informed consent requirements
The ELSI Committee began by reviewing consent
forms used in similar studies, such as the National
Human Genome Research Institute’s Haplotype
Map (HapMap) project [9] and the National Heart,
Lung, and Blood Institute’s Hemochromatosis and
Iron Overload Screening (HEIRS) study [10]. In
addition, network representatives surveyed local
investigators in various countries to determine if
our basic planned approach would be satisfactory
or if there were issues that the committee had not
considered. A draft consent form was circulated
and revised several times, including testing for
readability, before final approval by the Steering
Committee. The final form (Appendix 1) served as a
template that individual researchers could follow in
seeking Ethics Committee (EC) or Institutional
Review Board (IRB) approval. Additional model
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for participants in affected sibling pair and trio
families, including parents of minor study partici-
pants and assent forms for minor participants in
different age groups; later, model forms were
developed for case and control participants.
We recognized that consent practices differ
around the world, that various ECs and institutions
use different formats for consent forms, and that
different committees may require that additional
elements be added or that certain elements be
worded differently. An explanatory document was
therefore created to help guide investigators and
oversight bodies in revising and reviewing site-
specific consent forms (Appendix 2). Certain ele-
ments of the template were viewed as ethically
essential to research with humans [11–13], to
genetic and biobanking research [14–17], and to
this study, or were required to be standardized for
biobanking purposes.
The template was largely successful, as indicated
by its widespread adoption in different countries.
One aspect, however, proved somewhat problem-
atic. Following what were considered to be best
practices at the time, the template adopted a
structured consent format that, at the end, restated
each of the four core elements of the study (basic
participation, central storage of DNA for future
research, creation of cell lines, and recontact for
participation in future studies) and that required
the participant to signify agreement to each one
separately. The alternative to this ‘check-box’
approach would have been simply to signify con-
sent to the whole study as described in the entire
consent form. The difficulty presented by the
check-box approach was the tendency to look to
the recapitulations that accompanied the check
boxes, rather than to the fuller statement earlier in
the form, for the operative permissions language.
Because the check-box language necessarily was a
summation rather than a complete restatement, it
emphasized the genetic purposes of the study. As a
consequence, the check-box did not explicitly
restate that ordinary serum samples would be
stored for nongenetic studies related to diabetes.
The more focused check-box language, and inevi-
table variations in the translated versions, created
some issues for the central repository that had to be
resolved with the NIDDK Project Office.
Each researcher and country was allowed to
change the model form to meet their special needs
and concerns. Indeed, they could have entirely
rewritten the consent form if they chose. To avoid
the appearance of ethical imperialism and allow the
flexibility to accommodate widely varying prac-
tices, understandings, and social conditions around
the world, the ELSI Committee articulated a set of
basic ethical standards that would satisfy the
study’s core research ethics requirements, regard-
less of how they might be expressed in a particular
consent form. These were as follows:
(1) Each participant must be covered by a written
consent voluntarily signed by a person with
authority.
(2) The consent form must explain the basic nature
and purpose of the study in language that
participants or their authorized representatives
can understand.
(3) The form must give specific permission to send
blood samples to a regional network repository
and a central repository located in the United
States for storage and future research related to
diabetes or autoimmune disorders. (We felt it
important to mention the United States as the
final destination due to widespread anti-
American sentiment at the time.)
(4) The consent form must explain DNA or genetic
research in some way. Also, in order for cell
lines to be created, the consent form must
explain their nature and purpose in some way.
These core requirements presented no substan-
tive problems in any country. Indeed, despite this
flexibility to rewrite or write consent forms from
scratch, all participating institutions started with
the full template and most made only minor
adjustments. The only major change was that
some institutions declined to use the template’s
structure of granting consent separately and speci-
fically, using check-boxes, to each of four elements
of the study (described above).
To ensure that basic requirements were met, we
asked that revised consent forms be translated back
into English; these back-translated consent forms
served as the permanent record of their content.
The consent forms were then reviewed by NIDDK.
This review revealed a number of discrepancies in
the critical permission language that arose during
the translation and back-translation process – dis-
crepancies that initially escaped the attention of
the project’s staff. Consistency in this key language
is essential to central storage for future research. For
instance, some translated consents gave permission
to store and use only DNA, and not plasma and
serum, and some failed to mention the use of
samples in studying the complications of diabetes
or other autoimmune diseases. Some discrepancies
introduced conditions or qualifications that were
simply unacceptable to the central repository; for
instance, a requirement that a local institution
approve all future uses.
Several steps were taken to straighten out these
problems. Some minor discrepancies were resolved
simply by doing a more accurate back-translation
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clarifying interpretation that was consistent with
the model template. Other discrepancies required
the country to revise its approved consent form.
Because this review by the central repository was
not done at the earliest possible stage, it was
necessary in one country to re-consent some par-
ticipants who had been enrolled prior to correction
of the consent forms. A few samples were ulti-
mately destroyed when participants could not be
re-consented. Biosample collectors are well advised
to anticipate the likelihood of discrepancies of
language and meaning, and to ensure that consent
form changes and back-translations are reviewed as
early as possible by the eventual repository, cer-
tainly prior to initiating sample collections.
Although considerable effort was required to
adapt and translate consent forms for use in
multiple study sites in many countries, in many
respects, these challenges were quite similar to
those faced in any large multicenter study [18].
The IRBs at many sites request changes, and a
coordinated review of these changes is required to
ensure that local preferences are balanced appro-
priately with the requirements of the study.
Although this labor-intensive process is criticized
with some justification in single-country studies, it
is essential in multi-country studies. Fortunately,
our experience suggests that centralized review of
local changes to consent forms is workable and can
indeed achieve an effective balance.
Creation of cell lines
Collected samples were used to create immortalized
cell lines. Investigators were required to tell partic-
ipants that a cell line would be created unless they
objected, because it was felt that some people
might oppose having an ongoing means to produce
more of their DNA indefinitely, rather than only
the quantity of DNA that is extracted initially. The
following template language was used by most
sites: ‘To allow more researchers to work with your
blood sample, we are requesting permission to
produce and store a living cell line, which means
we will keep some of your white blood cells alive for
future research. If you agree, this will give research-
ers a large supply of DNA without needing to draw
additional blood samples.’
Nevertheless, people were given the option of
participating even if they objected to creating a cell
line. The other option would have been simply to
exclude objectors from the study, but there was
concern originally that this would make recruit-
ment more difficult. However, less than 1% of
participants in the Asia-Pacific, European, and
United Kingdom Networks exercised the option to
object to cell lines, but over 3% did so in the North
American Network. This suggests that concerns
about immortalized cell lines are low and are much
lower elsewhere in the world than they are in the
United States.
Uses of samples and information
The purpose of this study and future studies was
stated somewhat broadly to include the ‘complica-
tions’ of diabetes and ‘other autoimmune diseases.’
It would not be useful to store samples in a central
repository unless permission for a reasonable range
of related studies is given, because it is not feasible
to re-contact participants in more than 34 countries
or research groups each time a particular study is
proposed in the future.
The optimal scope of participants’ consent to
uses of biospecimens in future studies is one of the
liveliest controversies in genetic and biobanking
research [1–8,14–17]. Although many investigators,
scholars, and policy makers regard blanket consent
as the best means of promoting research progress,
others maintain that a narrower scope of research
makes participants’ consent more meaningful and
helps to guide oversight bodies’ review of future
proposed research.
To protect the rights of participants and the
Consortium’s purposes, other researchers are given
access only if they are qualified and they propose to
do relevant studies. In general, these requirements
mean that all investigators seeking to use T1DGC
samples and data must have their studies reviewed
and approved by an EC or IRB; limit their studies to
the purposes of the Consortium; provide informa-
tion about the investigators and their affiliations,
their funding sources, and the potential medical,
scientific, and commercial applications of the
research; ensure security of samples; agree not to
share or distribute samples; and agree to destroy
samples when work is done.
Contributing investigators, in order to pursue
their own research, received DNA and a cell line
from each participant’s sample they contributed to
the study. The Consortium therefore considered
how investigators may use these retained samples
collected from their own participants. In addition
to restricting use to the study of type 1 diabetes, its
complications, and other autoimmune diseases, the
following policies were adopted:
(1) If participants request to withdraw from the
T1DGC study, contributors must be able to
destroy their samples and information,
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investigator might give to their collaborators.
(2) Contributors may not (unless permitted by an
IRB or EC) attempt to identify their samples or
link them to information that could identify
the participants they came from, because they
were collected under the understanding that
they would be stored and studied anonymously.
(3) Contributors who wished to pursue other lines
of research, or make other uses of samples
beyond these restrictions, could do so only by
collecting additional samples outside of this
study, using a separate and different informed
consent.
Commercial uses
Intellectual property considerations are of increas-
ing importance in all areas of biotechnology
research, including genetic research [19–22]. The
debate over whether scientific progress is best
fostered by awarding patent rights or preserving
open access is ongoing. Information-sharing is
mandated by many research funders, prompting
the need to address the possibility of ‘downstream’
commercial uses of study data.
The philosophy of this study was to make
available as much information as possible, to as
many qualified researchers as possible, in order to
improve the health of people affected by type 1
diabetes. Therefore, this study placed its samples
and data in the public domain for the benefit of
science and medicine and did not claim any
intellectual property rights (other than rights to
control use and access to the database and
biobank).
However, it is possible that other researchers or
companies who have access to these public domain
materials may be able to use them to develop
something with commercial value or to claim
intellectual property in some product of their
research using these materials. The only way to
prevent such commercial uses and claims would be
to permit research access to only governments or
nonprofit organizations, but that would weaken
the purposes of the Consortium.
These policies allowing possible downstream
commercialization were acceptable in Europe,
North America, United Kingdom, and much of
the Asia-Pacific region, but several Asian countries
were concerned about commercial uses of their
samples. These countries were permitted, if they
wished, to flag their samples in the database as not
available to profit-making companies or for
researchers who intend to pursue commercial
development of their discoveries. Only India
ended up insisting on flagging their samples
this way. For Thailand, it was necessary to state
that the samples remained the property of the
collecting institution, even when they were sent to
the United States for central storage. This stipula-
tion was deemed acceptable because it did not
interfere with any of the Consortium’s or central
repository’s policies about storage, use, and
disposal.
Reporting results
Reporting the results of genetic research has
become another topic of considerable scholarly
and policy interest [14,23,24], in part because of
high expectations that the discovery of genetic
associations may lead rapidly to the development
of effective treatments, and in part because of the
difficulty in reconciling the limited value of com-
plex genetic information in clinical applications
with its inherent meaning for individuals. Thus,
whether or not to report the results of studies like
T1DGC is important both to determine and to
explain to all involved.
The Consortium did not report any results
directly to participants; it did only to investigators.
Each investigator was allowed to decide whether to
report any results to participants. Some investiga-
tors decided to report human leukocyte antigen
(HLA) genotyping or autoantibody test results in
the event that this information might be helpful for
refining clinical diagnoses or treatment plans. Also,
investigators always had the option of recontacting
participants to notify them of the option for
additional testing (without study funding) in the
event that subsequent research reveals genetic
information that has clinical importance.
Updates on the progress of the Consortium, its
findings, and its publications are reported on
the T1DGC website, which participants can access
if interested.
Government approvals
Any institution that receives federal funding for
human subjects research must have a ‘Federal Wide
Assurance’ (FWA) issued by the Department of
Health and Human Services’ (DHHS) Office of
Human Research Protections (OHRP). This FWA
requires a functioning EC that resembles the US’s
IRB and assurance of compliance with various basic
ethics standards. It was correctly anticipated that it
would be a burden to require investigators in
far-flung parts of the world to satisfy these require-
ments on their own. Initially, it was hoped that this
requirement could be avoided by paying local
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multi-country networks administered, out of insti-
tutions with FWAs in Melbourne, Australia;
Copenhagen, Denmark; Seattle, WA, USA; and
Cambridge, United Kingdom, rather than enabling
investigators to receive funds directly from NIH.
However, the DHHS ruled that each investigator
must affiliate with a local institution that has an
FWA. Therefore, staff in the four Network Centers
were trained in assisting investigators with using
the OHRP’s website to meet this requirement. Also,
to ease this burden, especially for investigators at
institutions without functioning ECs, investigators
were allowed to affiliate with institutions in their
country that had existing FWAs as long as that
institution’s EC agreed to assume oversight
responsibility.
Another regulatory issue that had to be negoti-
ated was the need in the United States to satisfy the
requirements of the Health Insurance Portability
and Accountability Act (HIPAA) privacy rule [25], in
order to send data to Consortium participants.
Similarly, the European Commission’s directive on
personal data privacy sets forth protections that
institutions in other countries must show before
they can receive personal medical data from
European countries [26]. To meet the European
requirements, the Coordinating Center had to
obtain certification for safe harbor status (similar
to the US’s FWA). To meet HIPAA requirements, the
Coordinating Center’s legal office initially expected
that we use its standard ‘data use agreement’, but
project leaders were concerned that it would alien-
ate contributing investigators if the United States
imposed yet another set of demanding regulatory
requirements, especially ones containing threaten-
ing legalese.
The solution devised was to redraft the data use
agreement to consist of a set of reciprocal assur-
ances between the Consortium and its members, in
a fashion that would satisfy both HIPAA’s require-
ments and those of the European Privacy Directive,
and therefore presumably also the laws of other
countries. In other words, rather than creating one
set of agreements under European law that covered
the sending of information to the Coordinating
Center, and a second set of agreements under US
law that covered the return of information to local
investigators, a single agreement was written that
served both purposes (Appendix 3). The reciprocity
created by putting these mutual assurances in the
same agreement helped to ease possible objections
to US legal and ethical imperialism. Also, it was
determined that this agreement needed to be
signed only by the Coordinating Center and the
four Network Centers, and not by individual con-
tributing investigators in each network. These
strategies worked well.
India and Thailand required approval by a
central government agency before local investiga-
tors could participate, and before blood and DNA
samples could be sent abroad. Their concern is that
national resources will be exploited or expropriated
for financial gain elsewhere, without commensu-
rate benefit for their citizens. Sometimes (as in
Thailand), government approval simply required
reviewing and revising the terms of a ‘material
transfer agreement’. Other times, this hurdle
proved to be considerable. In India, the process of
preparing the extensive proposal forms and shep-
herding them through the governmental review
process consumed over 3 years – threatening the
feasibility of that country’s full participation.
Conclusions and recommendations
As a long-term, large-scale international study,
T1DGC has dealt with most of the major ethical
and policy issues associated with biobanking, and
indeed has seen several ‘best practices’ change over
time. The Consortium faced fewer problems than
those reported by some other, similar studies
[27,28]. The Consortium’s success in identifying
and addressing ethical concerns did not come easily
but stems from several key strategies: (1) dedicating
sufficient time, personnel, and resources to ELSI
issues; (2) devoting hands-on attention to good
communication, in order to ensure that concerns
are understood and solutions are responsive and
implementable; (3) being able to persist, redo,
revise, and revisit in order to ensure that solutions
are implemented; and (4) following up continually,
and expecting new issues to arise over time.
Based on the experience in this study, several
important conclusions can be drawn as follows:
(1) Basic international standards for research ethics
review and informed consent are broadly con-
sistent across developed countries.
(2) When consent forms are adapted locally and
translated into different languages, discrepan-
cies are inevitable and therefore require prompt
central review and resolution before research
is initiated.
(3) Providing separate ‘check-box’ consent for dif-
ferent elements of a study creates confusion
and may not be essential.
(4) Creating immortalized cell lines to aid future
research is broadly acceptable, both in the
United States and internationally.
(5) Imposing some limits on the use of stored
samples aids in obtaining ethics approvals
worldwide.
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samples is controversial in some Asian
countries.
(7) Obtaining government approvals can be labor
intensive and time consuming, and can require
legal and diplomatic skills.
Although national, cultural, and language dif-
ferences gave rise to many of the ethical issues
encountered by T1DGC, many issues commonly
arise in similar multicenter studies conducted
entirely within the United States or Europe. Thus,
T1DGC has been something of a bellwether for
ethical issues in biobanking and genetic research.
Because the best ethics are preventive, we hope that
what we have learned can help others anticipate
and preemptively address these and similar issues
in their own research.
Acknowledgments
This research uses resources provided by the Type 1
Diabetes Genetics Consortium (T1DGC), a collabo-
rative clinical study sponsored by the National
Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK), the National Institute of Allergy
and Infectious Diseases (NIAID), the National
Human Genome Research Institute (NHGRI), the
National Institute of Child Health and Human
Development (NICHD), and the Juvenile Diabetes
Research Foundation International (JDRF), and
supported by U01 DK062418.
The authors thank the membership of the
T1DGC Ethical, Legal, and Social Implications
(ELSI) Committee for their contributions to this
article and to the work of the Consortium.
Members of the T1DGC ELSI Committee include
Carla Greenbaum, Mark Hall (Chair), Joan Hilner,
Simon Howell, Nancy King, Catherine McKeon,
Narinder Mehra, Giatgen Spinas, Elizabeth
Thomson, and Bart Van der Auwera.
References
1. Maschke KJ. Navigating an ethical patchwork – human
gene banks. Nat Biotechnol 2005; 23: 539–45.
2. European Society of Human Genetics. Data storage and
DNA banking for biomedical research: technical, social,
and ethical issues, 2001. Eur J Hum Genet 2003; 11: S8–10.
3. World Health Organization. Genetic databases: assessing
the benefits and the impact on human and patient rights,
2003. Available at: http://www.era.lib.ed.ac.uk/bitstream/
1842/2447/1/WHOreportGeneticDatabases.pdf (accessed
19 October 2009).
4. National Bioethics Advisory Committee. Research
involving human biological materials: ethical issues and
policy guidance, 1999. Available at: http://www.bioeth-
ics.gov/reports/past_commissions/nbac_biological1.pdf
(accessed 19 October 2009).
5. UNESCO. International declaration on human genetic
data. Available at: http://portal.unesco.org/shs/en/ev.php-
URL_ID¼1882&URL_DO¼DO_TOPIC&URL_SECTION¼
201.html (accessed 19 October 2009).
6. HUGO Ethics Committee, 2002. Available at: http://
www.hugo-international.org/img/genomic_2002.pdf
(accessed 19 October 2009).
7. National Cancer Institute. Best practices for biospeci-
men resources, 2007. Available at: http://biospecimens.
cancer.gov/global/pdfs/NCI_Best_Practices_060507.pdf
(accessed 19 October 2009).
8. Rothstein M, Knoppers B. Symposium, regulation of
biobanks. J Law Med Ethics 2005; 33: 7–101.
9. Hapmap. Available at: www.hapmap.org (accessed 19
October 2009).
10. McLaren CE, Barton JC, Adams PC, et al.
Hemochromatosis and iron overload screening (HEIRS)
study design for an evaluation of 100,000 primary care-
based adults. Am J Med Sci 2003; 325: 53–62.
11. National Commission for the Protection of Human
Subjects of Biomedical and Behavioral Research. The
Belmont Report: Ethical Principles and Guidelines for the
Protection of Human Subjects of Research. Department
of Health, Education and Welfare, Washington, DC,
1979. Available at: http://www.nihtraining.com/
ohsrsite/guidelines/belmont.html (accessed 19 October
2009).
12. Department of Health and Human Services, National
Institutes of Health, and Office for Human Research
Protections. The Common Rule, Title 45 (Public
Welfare), Code of Federal Regulations, Part 46
(Protection of Human Subjects). Available at: http://
www.hhs.gov/ohrp/humansubjects/guidance/
45cfr46.htm (accessed 19 October 2009).
13. Council of International Organizations of Medical
Sciences. International ethical guidelines for biomedical
research involving human subjects, 2002. Available at:
http://www.cioms.ch/frame_guidelines_nov_2002.htm
(accessed 19 October 2009).
14. Beskow LM, Burke W, Merz JF, Barr PA. Informed
consent for population-based research involving genet-
ics. JAMA 2001; 286: 2315–21.
15. Knoppers BM, Saginur M. Bio-banking. In: Singer PA,
Viens AM. (eds). The Cambridge Textbook of Bioethics.
Cambridge University Press, Cambridge, UK, 2008,
pp. 166–73.
16. Reilly PR, Boshar MF, Holtzman SH. Ethical issues in
genetic research: disclosure and informed consent. Nat
Genet 1997; 15: 16–20.
17. Hull SC, Gooding H, Klein AP, et al. Genetic research
involving human biological materials: a need to tailor
current consent forms. IRB 2004; 26: 1–7.
18. Blustein J, Regenstein M, Siegel B, Billings J. Notes
from the field: jumpstarting the IRB approval process in
multicenter studies. Health Serv Res 2007; 42: 1773–82.
19. Ossorio P. The human genome as common heritage:
common sense or legal nonsense? J Law Med Ethics 2007;
35: 425–39.
20. Brody B. Intellectual property and biotechnology: the
U.S. internal experience – Part I. Kennedy Inst Ethics J
2006; 16: 1–37.
21. Brody B. Intellectual property and biotechnology: the
U.S. internal experience – Part II. Kennedy Inst Ethics J
2006; 16: 105–28.
22. Brody B. Intellectual property and biotechnology: the
European debate. Kennedy Inst Ethics J 2007; 17: 69–110.
23. National Heart, Lung and Blood Institute. Working
Group on Reporting Genetic Results in Research Studies
Meeting Summary, 2004. Available at: http://www.nhlbi.
nih.gov/meetings/workshops/gene-results.htm (accessed
19 October 2009).
Biobanking and informed consent in the T1DGC S39
http://ctj.sagepub.com Clinical Trials 2010; 7: S33–S4524. Renegar G, Webster CJ, Stuerzebecher S, et al.
Returning genetic research results to individuals: points
to consider. Bioethics 2006; 20: 24–36.
25. Department of Health and Human Services. Standards
for Privacy of Individually Identifiable Health
Information, Final Rule, 67FR 53182-53273, 14 August
2002.
26. Baeyens AJ. Impact of the European Clinical Trials
Directive on academic clinical research. Med Law 2004;
23: 103–10.
27. McNay LA, Tavel JA, Oseekey K, et al. Regulatory
approvals in a large multinational clinical trial: the
ESPRIT experience. Control Clin Trials 2002; 23: 59–66.
28. Van Raak L, Hilton A, Kessels F, Lodder J.
Implementing the EGASIS trial, an international multi-
center acute intervention trial in stroke. Control Clin
Trials 2002; 23: 74–79.
Appendix 1
Model Informed Consent Form
[To be modified to meet requirements of Networks and
Ethics Committees. Words in [brackets] are optional
and sentences in italics are instructions. These should be
deleted in the final version of this form. It is permissible
to change the order of sentences or paragraphs. Other
changes also may be permissible, but they should be
discussed with the Network first. The final version of
this form must be translated back into English and sent
to the Regional Network Center.]
Type 1 Diabetes Genetics Consortium
Sponsor: United States National Institutes of
Health (NIH), National Institute of Diabetes &
Digestive & Kidney Diseases (NIDDK)
[Name of Local Institution]: ——————————
You are invited to participate in the Type 1
Diabetes Genetics Consortium. This is an interna-
tional effort to identify genes that affect the risk of
type 1 (or juvenile) diabetes. The researchers listed
below are in charge of this study at this institution.
Other staff will help or act for them, and they are
working with other researchers around the country
and the world who are also part of this study.
Before you can decide whether or not you should
agree to join this study, you should learn about its
risks and benefits. This is called informed consent.
If you decide to join the study, you will sign this
Informed Consent Form and you will have a copy
to keep for your records.
Purpose of the genetic study
Type 1 (or juvenile) diabetes is an important
health problem that affects many people.
Doctors know that genes (DNA) play a major role
in type 1 diabetes. This means that the risk for
developing type 1 diabetes can run in a family and
be passed from parents to children. Recent
advances in science allow doctors to study the
genes in families of people with a disease to learn
more about which genes affect the risk of the
disease. This can help to develop better treatments
or prevent health problems, which is why we are
conducting this study. However, to do this, lots of
different families are needed to provide samples of
their blood to analyze their genes (DNA). More
detailed information on this study is available on
the web site: www.t1dgc.org.
Description of the study
If you agree to be part of this study, we will take 3 to
5 tubes of blood (about 3 soup spoons [or 39mL])
from your arm and process this sample so that DNA
and other parts of your blood can be taken out,
stored, and used for research. We will also ask you
some questions about your health and your family.
This is being done for our research purposes only.
You will not learn anything through this research
about yourself or your family members. [Or: describe
policy for reporting results.]
With your permission, your blood samples and
information will be stored by —————[specify
local clinic] and also sent to storage locations in
—————— [specify regional network storage sites]
and a central repository in the United States so they
can be shared with other qualified researchers and
companies worldwide to study the genetics of type
1 diabetes, its complications, and other autoim-
mune diseases. These researchers may or may not
be part of this study. Because of the sensitive nature
of genetic materials, guidelines described below
have been developed to protect your privacy.
[Delete this sentence if there is a policy to report some
results:] You will not receive any information from
us after we take your blood sample. However, we
might ask for your help in contacting your family
members to participate in this study, and we might
contact you again for permission to collect addi-
tional samples or information.
Consent to produce a cell line
To allow more researchers to work with your blood
sample, we are requesting permission to produce
and store a living cell line, which means we will
keep some of your white blood cells alive for future
research. If you agree, this will give researchers a
large supply of DNA without needing to draw
additional blood samples. We will allow other
researchers to use your stored sample only to
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autoimmune diseases. [We will not do or allow any
human cloning.]
Ownership and right to have genetic
material destroyed
When you give your blood sample, you will no
longer own it or the genetic materials we obtain
from it. However, you have the right to request at
any time that your blood sample and genetic
materials be destroyed. Your request will be hon-
ored and we will tell you when your samples have
been destroyed.
Risks and discomforts
There are no major risks associated with drawing
blood. Having your blood drawn can be uncom-
fortable, occasionally causes bruising, and, in rare
cases, causes fainting. Only trained people will draw
your blood. There is also a very small risk that some
breach of confidentiality may occur. The specific
protections put in place to prevent this are discussed
in the confidentiality section of this form.
Benefits
There are no direct benefits to you from this study.
By participating in this study, you may or may not
help doctors develop better treatment or preven-
tion for type 1 diabetes, its complications, and
other autoimmune diseases. Throughout the study,
research findings will be posted on the web site:
www.t1dgc.org.
Alternatives and right to withdraw from the study
Participating in this study is entirely up to you. You
may refuse to participate or withdraw from the
study at any time, and this will not affect your
current or future health care or other benefits at
[Name of Institution].
Confidentiality
We will keep all of your medical and genetic
information confidential to the extent the law
allows. However, we cannot guarantee absolute
confidentiality. Information about you will not be
given to insurance companies, your employers, or
be used for any purposes other than those described
in this agreement. The information from this
research will be made widely available to
researchers, doctors, scientists and other people,
but your identity will not be released.
Your blood and DNA samples and the informa-
tion you give us will be stored in different places
under a code number, without your name or other
identifying information. However, we will still be
able to identify you if we need to for research
reasons.
Because other family members are participating
in this study, it is possible that we may find out
personal information that you or your relatives do
not know or do not want others to know [(for
example, that someone’s biological father is not
who they thought it was)]. If we discover this, we
will not tell you or anyone in your family under
any circumstances.
In some cases, people from the government
agency that is paying for this research, the U.S.
National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK), may need to see your
records to verify study information, but they will
not be told who you are. Also, the ————— [name
of institution’s Ethics Committee/IRB] may have
access to your records to ensure that your rights
are being properly protected.
Costs, compensation, and treatment
There is no charge to you for being in this study.
You will also not receive any payment for being in
this study. [Or: We will pay you $—— to cover your
travel or other expenses for being in this study.]
Your blood, DNA, and information will not be sold.
However, it is possible that information or mate-
rials from this study might be used to develop
products that have commercial value. If this hap-
pens, you will not receive any share of the profits.
We will not give you any treatment as part of this
study.
Questions
If you have any questions about your rights as a
research participant, please phone [include name of
Ethics Committee/IRB representative if appropriate] of
the Ethics Committee [Institutional Review Board],
at [insert phone number]. Moreover, if you have any
questions or concerns regarding this study, or if
problems arise, you may call the Principal
Investigator, [insert name], at [insert phone number].
Participant’s statement
I understand that, by participating in this study,
I agree:
A. To give 3 to 5 tubes of blood for storage,
processing, and research on the genetics of
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autoimmune diseases; to have blood tests done
relating to diabetes if needed; and to answer
questions about my health and my family,
understanding that this information will be
kept confidential at all times and that I can ask
to have my samples destroyed at any time.
« Yes
B. And, to allow my information and the DNA
extracted from my blood samples to be sent to
the United States and given to other qualified
scientists worldwide, even after this study ends,
to be analyzed for genetic information relating




C. To allow my genetic material to be made into a
living cell line that will create an unlimited
supply of DNA that can be used to study type 1
diabetes, its complications, and other autoim-
mune diseases.
« Yes « No
D. To be contacted in the future about possibly
participating in additional studies related to
diabetes, its complications, and other autoim-
mune diseases.
« Yes « No
Signatures
Your signature below shows that you have read this





Type 1 Diabetes Genetics Consortium Study
Investigators:
[include names, addresses, phone numbers]
Appendix 2
Explanation of Informed Consent Form
General comments
Because of the sensitivity of genetic information
and the complexity of a world-wide study, the
consent form used for T1DGC may be longer than
those used in clinical studies. Consent must be
signed and in writing. Each participant should
either consent or have someone with authority,
such as a parent or guardian, consent for them.
Parents may sign a consent form that covers more
than one child. If children are able to understand
the nature and purpose of the study, they can also
be given a consent form, or a simple explanation
can be read to them. This is called ‘assent’ rather
than ‘consent.’ For this purpose, there are two
versions of the assent form, one for small children
and the other for older children.
Each researcher and country may change the
model form to meet their special needs and
concerns. However, changes to the substance of
the form must be approved by the Network.
Consent forms must be translated into a partici-
pant’s native language. Translated versions of the
forms in other languages must be back-translated
into English to have a permanent record of the
content of the consent form.
Amount of blood drawn
Only three tubes will be drawn on children less
than 16 years old (22mL) and four tubes on
individuals who are 16 years or older (32mL). Five
tubes (an additional 5 or 7mL) will be drawn only
occasionally, for a quality assurance check, and
only from participants who are 16 years or older. In
the case of very small infants, the blood draw may
need to be less if local guidelines do not permit
three tubes to be drawn (based on the child’s
weight or total blood volume).
Reporting results
The Consortium will not report any results to
participants, only to investigators. Each investiga-
tor or ethics committee may decide whether to
report any results to participants. Most investiga-
tors will not report results because it is not expected
that testing will produce any clinically important
information. Antibody testing is being done only
on people already diagnosed with diabetes, not on
any unaffected family members. In its genetic
analysis, the Consortium expects only to identify
regions that require more detailed study.
Some investigators or ethics committees may
decide that they want to report HLA genotyping or
antibody test results. If so, they need to decide
whether these results will be reported to all partic-
ipants, or only to those where the results show
elevated risk or something the participant or their
physician is not already aware of. Investigators
should consider the burden (on themselves and on
participants) of explaining test results where
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anxiety may occur but there is no clear course of
action or treatment. If an investigator decides to
report some or all results, this policy needs to be
described accurately in the consent form.
It is possible that, in the future, particular
researchers could use Consortium resources to
identify a specific gene that identifies susceptibility
to diabetes, but that possibility is too uncertain to
offer as a potential benefit of the study. If this
were to happen, investigators always have the
option of recontacting participants to notify them
of the possibility for additional testing, but this
will need to be paid for from sources outside of
this study.
False paternity
The model form suggests telling participants that
they will not be notified if some indication is found
‘that someone’s biological father is not who they
thought it was.’ This is a study policy that cannot
be changed, in part because indications of possible
false paternity will not be conclusively confirmed.
However, it is optional whether or not to notify
participants specifically about this policy. Some
institutions may prefer not to raise this issue.
DNA and cell lines
It is necessary to tell participants that a cell line will
be created, because some people may object to this.
However, people can still participate in the study if
they refuse permission for a cell line, but then
researchers will be limited to working with only the
quantity of DNA that is extracted initially. Creating
a cell line promotes the interests of research
participants because it reduces the amount of
blood that it is necessary to remove. This is
particularly important for studies like this that
involve small children or infants. It has sometimes
happened in the past that genetic studies have
exhausted the stored DNA samples before the study
is successfully completed, but when success is still
possible. This defeats the purpose of asking people
to participate and to donate their samples.
The model form explains that a cell line is not
the same as human cloning and that no human
cloning will be done or will be allowed by this
study. This policy will not change. However, it
is optional whether to include this language
that specifically raises this issue, or instead to
only explain this if a person asks about the issue
of cloning.
Future studies
DNA and information will be stored and released to
other researchers only in a strictly anonymous
form. Also, this will be done only for diabetes-
related studies by qualified researchers that are
approved by ethics committees (IRBs) and that
meet the requirements established by the
Consortium; these are described further below.
The purpose of this study and future studies is
stated somewhat broadly to include ‘‘other auto-
immune diseases’’ because the basic mechanisms
that trigger type 1 diabetes are poorly understood,
and it may be important to study autoimmunity
as a general phenomenon in order to understand
what causes type 1 diabetes. Also, the consent
form allows future studies of the ‘complications’
of diabetes. However, the actual range of compli-
cations or autoimmune diseases that is feasible to
study is limited to the particular conditions that
participants are asked about in the health ques-
tionnaires. These include multiple sclerosis, celiac
disease, thyroid disease, myasthenia gravis, perni-
cious anemia, lupus, rheumatoid arthritis, inflam-
matory bowel disease, vitiligo, Addisons disease,
and psoriasis. The DNA samples are not useful for
a central repository if this permission is not
given, because it is not feasible to re-contact
participants in 34 countries or research groups
each time a particular study is proposed in the
future.
Commercial uses
The philosophy of this study is to make available as
much information as possible, to as many qualified
people as possible, in order to improve the health of
people affected by this devastating disease. The
Consortium was established because leading
researchers believed that existing collections of
DNA samples were too small and kept by separate
researchers. Therefore, this study intends to pool all
available DNA and place it in the public domain for
the benefit of science and medicine. The
Consortium will not claim any intellectual property
rights in this DNA, it will not sell the DNA, and it
will not, itself, develop any commercial products
from this DNA or the related information.
However, it is possible that other researchers or
companies who have access to these public domain
materials may be able to use them to develop
something with commercial value. The DNA itself
will not be commercialized; it is only possible that
the DNA might be raw material that is used to
develop a commercial application. The only way to
prevent this is to deny access to the materials, both
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defeat the purposes of the Consortium.
To protect the rights of participants and the
Consortium’s purposes, other researchers will be
given access only if they are qualified and they
propose to do relevant studies. Exact requirements
for qualification are still being developed by the
Consortium’s Access Committee. In general, the
Consortium will require that other researchers and
companies:
  Honor the Consortiums’ rules about ownership
and intellectual property
  Have their studies approved by Ethics
Committees (IRBs)
  Limit their studies to the purposes of the
Consortium
  Provide detailed information about the purpose
and nature of the study, the funding sources,
the investigators and their affiliations, the poten-
tial medical, scientific, and commercial applica-
tions of the research, and other relevant
considerations
  Ensure security of samples, do not share or
distribute samples, and destroy samples when
work is done
  Sign a pledge form to abide by T1DGC publica-
tions policies, the consent guidelines conferred
by study participants, and T1DGC policies related
to ownership of specimens and patent rights
Compensation
It is optional whether or not to compensate partic-
ipants, but if there is any compensation, it should
only be for expenses, not as payment to ‘purchase’
participation. Institutions are free to modify the
suggested language to fit the circumstances of their
particular compensation policies.
[North American Version Only:]
Confidentiality
The section of confidentiality, and language else-
where in the form, is intended to comply with the
new U.S. privacy law known as HIPAA, which
requires a detailed explanation of where data is kept
and who has access to it. Also, HIPAA requires that
certain other statements be included that might
appear unusual or unnecessary. With these provi-
sions in the consent form, it is not necessary to
have a separate HIPAA ‘authorization form’ signed,




This DATA USE AGREEMENT (‘the Agreement’) is
effective the ——day of —————, 2006, by and
between Wake Forest University Health Sciences
(‘Wake Forest’), and —————— (‘Participant’).
RECITALS:
WHEREAS, Wake Forest and Participant are part of
the Type 1 Diabetes Genetics Consortium (the
‘Consortium’), whose general purpose is to identify
genes that determine an individual’s risk of type 1
diabetes;
WHEREAS, the Consortium requires the transfer,
sharing, analysis, and other uses of various types of
medical data among the many institutions that are
participating internationally;
WHEREAS, medical data is regulated by various
laws, regulations, protocols, and guidelines in both
the United States and in other countries that are
part of the Consortium, which the parties to this
agreement wish to comply with;
NOW, THEREFORE, in consideration of the
mutual agreements, covenants, terms and condi-
tions herein contained, Wake Forest and
Participant agree as follows:
I. Transfer and use of limited data
Section 1.1 Activities. Wake Forest and Participant
will use and transfer data under this agreement
only for the research purposes of the Consortium,
specified in its Consortium Agreement, its
Statement of Purposes, and its Specific Aims, as
they may be modified from time to time.
Section 1.2 Limited Data. Wake Forest and
Participant will transfer to each other data that is
collected through the forms and protocols estab-
lished by the Consortium, as they may be amended
from time to time. Wake Forest and Participant
acknowledge that these data elements are the
minimum necessary for accomplishing the research
purposes of the Consortium. Data that are trans-
ferred between Wake Forest and Participant will not
contain any of the following information that can
be used to identify the research participant or their
relatives, household members or employers: names,
telephone numbers, fax numbers, street addresses,
electronic mail addresses, social security numbers,
medical record numbers, insurance identification
numbers, account numbers, certificate/license
numbers, vehicle identifiers and serial numbers
(including license plate numbers) device identifiers
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Locators (URLs); Internet Protocol (IP) address
numbers, biometric identifiers, full face photo-
graphic images and comparable images. Data with-
out these personal identifiers shall be known as
‘Limited Data.’
Section 1.3. Use of Limited Data. Wake Forest and
Participant may use and disclose the Limited Data
only as permitted under the terms of this
Agreement or required by law, but shall not other-
wise use or disclose the Limited Data and shall
ensure that its directors, officers, employees, con-
tractors and agents do not use or disclose the
Limited Data in any manner that would constitute
a violation of this Agreement or applicable law.
Wake Forest and Participant agree not to use the
Limited Data in such a way as to identify any
individual and further agree not to contact any
individual who might be identified using this data.
Data User shall limit the use or receipt of the
Limited Data to the individuals who reasonably
need the Limited Data for the performance of the
Consortium’s Activities. Wake Forest and
Participant shall use appropriate safeguards to
prevent use or disclosure of the Limited Data
other than as permitted under this Agreement.
Section 1.4. Reporting of Disclosures of Protected
Health Information. Wake Forest or Participant
shall, within thirty (30) days of becoming aware of
any use or disclosure of the Limited Data in
violation of this Agreement, report any such use
or disclosure to the other party to this Agreement.
Section 1.5. Notice of Request for Data. Wake
Forest and Participant agree to notify the other
party within (7) business days if it receives an
official request or legal subpoena for any Limited
Data. To the extent that one party decides to
challenge the validity of such request, the other
party shall cooperate fully in such challenge.
Section 1.6. Agreements by Third Parties. Wake
Forest and Participant shall obtain and maintain an
agreement with each agent or subcontractor that
has or will have access to the Limited Data, which
requires such agent or subcontractor to be bound
by the same restrictions, terms and conditions that
apply to the Limited Data under this Agreement.
II. General provisions
Section 2.1. Termination Upon Breach. Any other
provision of this Agreement notwithstanding, this
Agreement may be terminated by either party upon
fifteen (15) days written notice (including e-mail)
to the other party in the event that the second
party breaches any provision contained in this
Agreement and such breach is not cured within
such fifteen (15) day period. Wake Forest and
Participant acknowledge and agree that in the
event the other’s efforts to cure any breach are
unsuccessful, the first party has a duty to discon-
tinue use of the Limited Data, notwithstanding
any other provision of this Agreement to the
contrary.
Section 2.2. Return or Destruction of Data upon
Termination. If this Agreement is terminated due
to breach of the Agreement, the breaching party
shall either return or destroy all data received from
the other party that the breaching party maintains
in any form. The breaching party shall not retain
any copies of such data. Notwithstanding the
foregoing, to the extent that the non-breaching
party agrees that it is not feasible to return or
destroy such data, the terms and provisions of this
Agreement shall survive termination of the
Agreement and such data shall be used or disclosed
solely as required by the reasons that prevented
their return or destruction.
Section 2.3. Injunction. Wake Forest and
Participant each acknowledge and agree that the
other party will suffer irreparable damage if it
breaches this Agreement and that damages from
such breach shall be difficult to quantify. Therefore,
Wake Forest and Participant acknowledge and agree
that an action for an injunction may be filed to
enforce the terms of this Agreement, in addition to
any other remedy the law may provide.
Section 2.4. Effect. The terms and provisions of this
Agreement shall supercede any other conflicting or
inconsistent agreements between Wake Forest and
Participant, including all exhibits or other attach-
ments thereto and all documents incorporated
therein by reference.
IN WITNESS WHEREOF, the parties have caused
this Agreement to be executed as of the day and
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